Although volume was light, October was a robust month for M&A deal making in terms of impact, especially in the cancer diagnostics space. The month started with the announcement of Invitae’s acquisition of liquid biopsy testing firm ArcherDx for $1.4 billion and ended with a pair of strategic acquisitions of early cancer detection firms by…
Exact Sciences Makes a Bold Double Play to Bolster Its Early Cancer Detection Capabilities
Although volume was light, October was a robust month for M&A deal making in terms of impact, especially in the cancer diagnostics space. The month started with the announcement of Invitae’s acquisition of liquid biopsy testing firm ArcherDx for $1.4 billion and ended with a pair of strategic acquisitions of early cancer detection firms by […]
